NURO vs. DXR, WOK, POCI, COCH, PYPD, XAIR, SURG, DHAI, IRIX, and NXGL
Should you be buying NeuroMetrix stock or one of its competitors? The main competitors of NeuroMetrix include Daxor (DXR), WORK Medical Technology Group LTD Ordinary Shares (WOK), Precision Optics (POCI), Envoy Medical (COCH), PolyPid (PYPD), Beyond Air (XAIR), SurgePays (SURG), DIH Holding US (DHAI), IRIDEX (IRIX), and NEXGEL (NXGL). These companies are all part of the "medical equipment" industry.
NeuroMetrix vs.
NeuroMetrix (NASDAQ:NURO) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation.
Daxor has a consensus price target of $24.75, indicating a potential upside of 241.85%. Given Daxor's stronger consensus rating and higher probable upside, analysts plainly believe Daxor is more favorable than NeuroMetrix.
NeuroMetrix received 283 more outperform votes than Daxor when rated by MarketBeat users. However, 100.00% of users gave Daxor an outperform vote while only 57.49% of users gave NeuroMetrix an outperform vote.
Daxor has lower revenue, but higher earnings than NeuroMetrix.
NeuroMetrix has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.46, meaning that its stock price is 146% less volatile than the S&P 500.
Daxor has a net margin of 0.00% compared to NeuroMetrix's net margin of -203.71%. Daxor's return on equity of 0.00% beat NeuroMetrix's return on equity.
19.4% of NeuroMetrix shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 7.3% of NeuroMetrix shares are owned by insiders. Comparatively, 59.0% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Daxor had 2 more articles in the media than NeuroMetrix. MarketBeat recorded 3 mentions for Daxor and 1 mentions for NeuroMetrix. NeuroMetrix's average media sentiment score of 0.00 equaled Daxor'saverage media sentiment score.
Summary
Daxor beats NeuroMetrix on 10 of the 14 factors compared between the two stocks.
Get NeuroMetrix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroMetrix Competitors List
Related Companies and Tools
This page (NASDAQ:NURO) was last updated on 2/22/2025 by MarketBeat.com Staff
